0.6980
-0.0780
(-10.05%)
At close: January 30 at 5:29:37 PM GMT+1
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
2,016.8380
2,131.9740
1,814.3670
1,476.3560
1,400.5630
Cost of Revenue
128.9750
201.2610
110.8700
295.1040
193.6950
Gross Profit
1,887.8630
1,930.7130
1,703.4970
1,181.2520
1,206.8680
Operating Expense
9,425.0290
9,812.9720
9,138.3660
9,163.7550
8,363.3480
Operating Income
-7,537.1660
-7,882.2590
-7,434.8690
-7,982.5030
-7,156.4800
Net Non Operating Interest Income Expense
252.1940
213.5900
2.1890
0.6870
--
Pretax Income
-7,284.9720
-7,668.6690
-7,432.6800
-7,981.8160
-7,156.4800
Net Income Common Stockholders
-7,284.9720
-7,668.6690
-7,432.6800
-7,981.8160
-7,156.4800
Diluted NI Available to Com Stockholders
-7,284.9720
-7,668.6690
-7,432.6800
-7,981.8160
-7,156.4800
Basic EPS
-0.25
-0.29
-0.43
-0.52
-0.47
Diluted EPS
-0.25
-0.29
-0.43
-0.52
-0.47
Basic Average Shares
26,074.3950
26,074.3950
17,382.9320
15,275.0270
15,275.0270
Diluted Average Shares
26,074.3950
26,074.3950
17,382.9320
15,275.0270
15,275.0270
Total Operating Income as Reported
-7,323.5760
-7,668.6690
-7,432.6800
-7,982.4250
-7,156.4800
Total Expenses
9,554.0040
10,014.2330
9,249.2360
9,458.8590
8,557.0430
Net Income from Continuing & Discontinued Operation
-7,284.9720
-7,668.6690
-7,432.6800
-7,981.8160
-7,156.4800
Normalized Income
-7,284.9720
-7,668.6690
-7,432.6800
-7,981.8160
-7,156.4800
Interest Income
252.7480
214.1440
2.2540
0.6870
--
Interest Expense
0.5540
0.5540
0.0650
--
--
Net Interest Income
252.1940
213.5900
2.1890
0.6870
--
EBIT
-7,284.4180
-7,668.1150
-7,432.6150
-7,981.8160
-7,156.4800
EBITDA
-7,062.9180
-7,448.1150
-7,227.6150
-7,774.2160
-6,919.2690
Reconciled Cost of Revenue
128.9750
201.2610
110.8700
295.1040
193.6950
Reconciled Depreciation
221.5000
220.0000
205.0000
207.6000
237.2110
Net Income from Continuing Operation Net Minority Interest
-7,284.9720
-7,668.6690
-7,432.6800
-7,981.8160
-7,156.4800
Normalized EBITDA
-7,062.9180
-7,448.1150
-7,227.6150
-7,774.2160
-6,919.2690
6/30/2021 - 5/4/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BIOVIT.ST Bio Vitos Pharma AB (publ)
0.1370
+1.48%
SPEC.ST SpectraCure AB (publ)
2.0150
-7.57%
QLIFE.ST Qlife Holding AB (publ)
2.1400
-2.73%
QLINEA.ST Q-linea AB (publ)
0.3115
-2.81%
SERA Sera Prognostics, Inc.
6.65
+5.72%
XVIVO.ST Xvivo Perfusion AB (publ)
470.00
+2.62%
WOK WORK Medical Technology Group LTD
2.3100
-6.85%
HSCS HeartSciences Inc.
3.3000
0.00%
OWLT Owlet, Inc.
4.6000
+2.00%
CRGT Cortigent, Inc.
0.0000